(Bloomberg) -- Italian drugmaker Angelini Pharma SpA is looking at three US biotechs for a potential merger that would expand its global footprint and help it execute an ambitious growth plan. Most Read from Bloomberg Canada’s Immigration Minister Has a Message for Foreign Students: You Can’t All Stay Brookfield Lines Up a 36-Year-Old Rising Star as Next Billionaire CEO US Floats Tougher Trade Rules to Rein In China Chip Industry Biden Faces Intensified Calls to Step Aside While Ill With Covid High-Flying Chipmakers See Worst Plunge Since 2020: Markets Wrap Sergio Marullo di Condojanni, the chief executive officer of the drugmaker’s Rome-based holding company, Angelini Holding SpA, said in an interview that the ideal partner would have a pipeline of products in late clinical trials, and have released at least one drug to treat epilepsy, depression or schizophrenia. He declined to name any of the prospective counterparties. “We’re currently reviewing a shortlist of about three biotech firms which are all focused on central nervous system diseases,” Marullo di Condojanni said. Angelini recently hit an all-time high of €2.1 billion ($2.3 billion) in revenue, with its largest business, Angelini Pharma, reporting €1.2 billion in sales last year, according to a statement seen by Bloomberg. While Marullo said Angelini is particularly interested in expanding into the US, where it does not currently have a presence, Bloomberg News reported last month that the company has also expressed interest in Milan-listed Italian drugmaker Recordati SpA. That came after buyout firm CVC Capital Partners Plc kicked off discussions about selling its controlling stake, according to people familiar with the matter. A deal with Recordati would be a transformational move for Angelini, creating an Italian pharma powerhouse that could generate overall sales of about €3.3 billion and would employ about 7,500 workers, according to the companies’ latest annual reports. Angelini has yet to submit a formal proposal for Recordati, the people said. A spokesperson for CVC declined to comment. Angelini group’s sales rose year-over-year about 8% in 2023 to €2.1 billion, according to the statement, which Marullo di Condojanni characterized as the company’s best-ever financial performance. Over that same period, earnings before interest, taxes, depreciation and amortization climbed 19% to €304 million. In 2021, Angelini agreed to buy Swiss-based Arvelle Therapeutics, which makes seizure drugs, in an all-cash deal worth as much as $960 million. Thanks to investments totaling around €800 million, Marullo di Condojanni said that the company’s revenue has risen more than 25% over the past four years. The drugmaker, which was founded in the central Italian town of Ancona in 1919 by pharmacist Francesco Angelini, is known for making popular over-the-counter medications for pain relief. It currently operates 12 plants, half of which are in Italy. --With assistance from Albertina Torsoli and Swetha Gopinath. Most Read from Bloomberg Businessweek Top Takeaways From Businessweek’s Donald Trump Interview Why the Nobel-Laureate Pioneer of Microfinance Risks Life in Jail How Trader Joe’s Mini Cooler Bags Became a Viral Hit Interviewing Trump on His Plans for the US Economy What Americans Invest In Now ©2024 Bloomberg L.P.
Italy’s Angelini Eyes Major Pharma Merger to Boost Drug Pipeline
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...